Natural proteins and polysaccharides in the development of micro/nano delivery systems for the treatment of inflammatory bowel disease

• Published in: International journal of biological macromolecules 2020-12, Vol.165 (Pt A), p.722-737
• Main Authors: Shah, Brijesh M., Palakurthi, Sushesh Srivatsa, Khare, Tripti, Khare, Sharad, Palakurthi, Srinath
• Format: Article
• Language: English
• Subjects: Animals; Biomacromolecules; Colon targeting; Disease Models, Animal; Drug Carriers - chemistry; Drug Carriers - therapeutic use; Gut microbiota; Humans; Immunosuppressive Agents - chemistry; Immunosuppressive Agents - therapeutic use; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - immunology; Inflammatory Bowel Diseases - pathology; Nanohybrids; Nanostructures - chemistry; Nanostructures - therapeutic use; Oral delivery; Polysaccharides - chemistry; Polysaccharides - therapeutic use
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2020.09.214

Treatments for inflammatory bowel disease (IBD) are typically immunosuppressive. Despite a range of treatment options, limited efficacy, systemic toxicities like bone marrow suppression, infections and malignancy are their serious setbacks. There exists an unmet medical need for novel therapeutic agents without safety concerns resulting from chronic, systemic immunosuppression. Of late, several natural agents with better therapeutic potential have been reported. It is very likely that restricting the release of the active molecules to the intestine would further improve their clinical efficacy and safety. To this end, novel polymer-based micro/nano formulations protect the drug from gastric environment and slowly release the drug in the colon. However, cost and side-effects associated to synthetic polymers have led to the development of biocompatible, economic and pharmaceutically well-accepted biomacromolecules in exploring their potential in IBD. Since last few years, biological proteins, polysaccharides and their combinations have shown great efficacy in colitis induced animal models. In this review, micro/nano formulations developed using biomacromolecules like chitosan, zein, pectin, casein, alginate, dextran, glucomannan and hyaluronic acid have been reviewed focusing on their potential in protecting active cargo, avoiding premature release, distal colon targeting along with their impact on reshaping the altered gut microbiota and how it can ameliorate the colitis conditions.